Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank71
3Y CAGR-19.7%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-19.7%/yr
Annual compound
Percentile
P71
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 10.79% |
| 2024 | 134.97% |
| 2023 | 13.34% |
| 2022 | 20.83% |
| 2021 | -86.77% |
| 2020 | -30.39% |
| 2019 | 54.49% |
| 2018 | -21.07% |
| 2017 | -121.91% |
| 2016 | -52.18% |